Clinical-Stage Biopharmaceuticals

Vogenx, Inc.

Investor Relations · Nasdaq: VOGX

Vogenx is a clinical-stage biopharmaceutical company developing novel therapies for serious diseases associated with dysfunctions in human metabolism — including post-bariatric hypoglycemia and gastroparesis — led by mizagliflozin, an oral SGLT1 inhibitor in Phase 2 development.

Stock Snapshot — Nasdaq: VOGX

Last updated: —

News & SEC Filings

The latest company announcements and regulatory filings, updated automatically.

Stay Informed

Subscribe to Vogenx IR alerts and receive press releases, SEC filings, and investor updates directly to your inbox.

We respect your privacy. Unsubscribe at any time.

Investor Relations Contact

Questions from investors and analysts are welcome.

Frequently Asked Questions

What does Vogenx, Inc. do?

Vogenx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia and gastroparesis.

What is the ticker symbol for Vogenx?

Vogenx, Inc. is listed on the Nasdaq Capital Market under the ticker symbol VOGX.

What is mizagliflozin?

Mizagliflozin is Vogenx's lead product candidate — an orally administered, selective small-molecule SGLT1 inhibitor in Phase 2 clinical development for post-bariatric hypoglycemia, with planned Phase 2 development in gastroparesis.

What industry is Vogenx in?

Vogenx operates in the clinical-stage biopharmaceutical industry, developing therapies for metabolic diseases.

Where is Vogenx headquartered?

Vogenx, Inc. is headquartered at 3901 Barrett Drive, Suite 300, Raleigh, North Carolina 27619.

How do I contact Vogenx Investor Relations?

Email info@vogenx.com or call +1 (919) 659-5677.